TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea
This collaboration with EyeGene is expected to represent the first clinical-stage program to use GMP-grade modified uridine triphosphate, with an intended use for further processing, manufactured by TriLink.
- This collaboration with EyeGene is expected to represent the first clinical-stage program to use GMP-grade modified uridine triphosphate, with an intended use for further processing, manufactured by TriLink.
- As part of these efforts, TriLink is excited to be expanding its collaboration with EyeGene in South Korea.
- TriLink and EyeGene met on September 21, 2021, at the KORUS Global Vaccine Business Roundtable held in New York, to discuss their continued collaboration as EyeGene advances development of its vaccine into phase 1 clinical testing and beyond.
- EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000.